JAVIER
SASTRE VALERA
Profesor asociado de Ciencias de la Salud
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (11)
2023
2022
-
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
European Journal of Cancer, Vol. 177, pp. 154-163
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
-
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)
Health and Quality of Life Outcomes, Vol. 19, Núm. 1
2018
-
Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer
International Journal of Cancer, Vol. 143, Núm. 8, pp. 1954-1962
2017
-
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain
Clinical and Translational Oncology, Vol. 19, Núm. 4, pp. 498-507
-
Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients
Journal of the National Cancer Institute, Vol. 109, Núm. 4
2014
-
Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
Clinical and Translational Oncology, Vol. 16, Núm. 11, pp. 942-953
2013
-
Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. the large experience of the spanish national tumor registry (RGETNE)
Neuroendocrinology, Vol. 98, Núm. 2, pp. 156-168
-
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)
European Journal of Cancer, Vol. 49, Núm. 18, pp. 3780-3787
2010
-
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE)
Annals of Oncology, Vol. 21, Núm. 9, pp. 1794-1803